Thermo Fisher Launches CorEvidence for Advanced Clinical Research

Thermo Fisher Scientific has announced the data lake platform CorEvidence, designed to revolutionize pharmacovigilance case processing, clinical research registries, and safety data management.

Thermo Fisher Scientific has launched CorEvidence, a cloud-based platform designed to optimize pharmacovigilance in clinical research registries. This innovative tool enhances clinical research by streamlining processing and safety data management. Acquired in 2023, CorEvitas, with its registries and data platform, supports crucial post-authorization safety studies, significantly impacting patient safety and medical research through the efficient collection of real-world evidence.

CorEvidence

CorEvidence is a comprehensive solution aimed at enhancing the effectiveness and efficiency of clinical research registries. Its initial application is set to streamline the workflow and management of pharmacovigilance, a critical component of patient safety in the post-authorization phase of drug development.

Impact on Patient Safety and Medical Research

Christine Barr, Vice President of Pharmacovigilance at CorEvitas, highlights the platform's capability to effectively address complex pharmacovigilance business needs. "We look forward to the positive impact this system will have on our customers and, most importantly, the well-being of the patients and our medical communities who depend on timely availability of real-world evidence and ongoing benefit/risk assessment activities to inform the safe use of pharmaceutical products."

The Core Features

The platform is uniquely equipped to handle a myriad of data sources, simplifying the intricate processes of coding, classifying, and reporting adverse events and safety occurrences. It's an end-to-end solution that covers the full spectrum of pharmacovigilance deliverables, ensuring efficient, traceable, auditable, scalable, and compliant safety management.

Thermo Fisher's acquisition of CorEvitas in August 2023 marked a significant expansion of its capabilities in providing gold-standard real-world evidence solutions. CorEvitas is known for its 12 registries, including nine in autoimmune and inflammatory diseases, and a data intelligence platform that manages clinical registries across various therapeutic areas. This platform encompasses data from over 400 investigator sites and tracks more than 100,000 patients longitudinally.

The Regulatory and Clinical Impact

The CorEvitas model is integral to fulfilling regulatory requirements for numerous long-term post-authorization safety studies across various disease indications. This model exemplifies the increasing importance of comprehensive and robust data in guiding clinical decisions and regulatory compliances. The launch of CorEvidence by Thermo Fisher Scientific marks a crucial step in the journey towards enhancing patient safety and the efficacy of clinical research. 

About Author: Mithat Can Turan

I am a software developer and a 4th-year Computer Engineering student at the Turkish-German University. I have worked on numerous software projects, especially those related to healthcare. My primary interests lie in digital health and AI applications within healthcare projects. I closely follow the latest developments in AI and digital health.